TRIPOD Checklist: Prediction Model Development and Validation

Section	Item		Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract					
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	Page1/Line3-6	Title/Paragraph1
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	Page2-3/Line36-67	Abstract/Paragraph1-4
Introduction					
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	Page4-5/Line85-106	Introduction/Paragraph1-2
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	Page5/Line107-115	Introduction/Paragraph2
Methods					
Source of data	4a	D;V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, ifapplicable.	Page5-6/Line120-140	Methods/Paragraph1
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	Page6/Line136-140	Methods/Paragraph1
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	Page5-6/Line120-127	Methods/Paragraph1
	5b	D;V	Describe eligibility criteria for participants.	Page6/Line127-136	Methods/Paragraph1
	5c	D;V	Give details of treatments received, if relevant.	N/A(Ending event for the occurrence of ACS)	N/A(Ending event for the occurrence of ACS)
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	Page5/Line111-115 Page9/Line196-201	Introduction/Paragraph2 Methods/Paragraph6
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	Page6/Line127-131 Page9/Line192-196	Methods/Paragraph1 Methods/Paragraph6
Predictors	7a	D;V	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	Page7-9/Line156-190	Methods/Paragraph3-5
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	Supplementary MaterialPage1/Line7-9	Supplementary MaterialParagraph1
Sample size	8	D;V	Explain how the study size was arrived at.	Page9/Line192-196 Page14-15/Line319-322	Methods/Paragraph6 Discussion/Paragraph1

Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	Page6/Line134-136	Methods/Paragraph1
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	Page9/Line192-194	Methods/Paragraph6
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	Page9/Line194-196	Methods/Paragraph6
	10c	V	For validation, describe how the predictions were calculated.	Page9/Line196-199	Methods/Paragraph6
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	Page9/Line196-201 Supplementary Material	Methods/Paragraph6 Supplementary Material
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	N/A (no update)	N/A (no update)
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	N/A(No Risk Group)	N/A(No Risk Group)
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	Table 1-2 Page10/Line224-226	Table 1-2 Results/Paragraph1
Results					
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	Page10/Line212-223 Figure 1	Results/Paragraph1 Figure 1
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	Page10/Line223-224 Page10-11/Line228-240 Table 1-2	Results/Paragraph1 Results/Paragraph2 Table 1-2
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	Table 1-2 Page10/Line224-226	Table 1-2 Results/Paragraph1
Model development	14a	D	Specify the number of participants and outcome events in each analysis.	Page10/Line219-223 Figure 1 Table 1	Results/Paragraph1 Figure 1 Table 1
	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	Table 3 Page11/Line242-244	Table 3 Results/Paragraph3
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	Table 4 Figure 3-4 Page11-12/Line246-276 Page13/Line284-289	Table 4 Figure 3-4 Results/Paragraph3-6
	15b	D	Explain how to the use the prediction model.	Figure 4	Figure 4
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	Table 4 Page11-12/Line253-262 Page12/Line268-273	Table 4 Results/Paragraph4 Results/Paragraph5
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	N/A (no update)	N/A (no update)
Discussion					
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	Page17/Line364-381	Limitations /Paragrap1

Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	Supplementary MaterialPage2/Line62-68 Page15/Line321-324	Supplementary Material/Paragraph8 Discussion/Paragraph1
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.	Page15-16/Line325-347	Discussion/Paragraph2-3
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	Page16/Line348-362	Discussion/Paragraph4
Other information					
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	Supplementary Material	Supplementary Material
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	Page18/Line390-396	Acknowledgement/Paragraph1

* Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

Article information: https://dx.doi.org/10.21037/qims-22-1045

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.